190 related articles for article (PubMed ID: 38619623)
1. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract][Full Text] [Related]
2. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
4. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
6. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
[TBL] [Abstract][Full Text] [Related]
8. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
10. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
[TBL] [Abstract][Full Text] [Related]
11. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).
Hui Z; Zhang J; Ren Y; Li X; Yan C; Yu W; Wang T; Xiao S; Chen Y; Zhang R; Wei F; You J; Ren X
Cell Death Dis; 2022 Jul; 13(7):607. PubMed ID: 35831283
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-1 is a valuable biomarker for predicting response of advanced non-small cell lung cancer patients to hypofractionated radiotherapy and PD-1 blockade.
Kang P; Li Y; Hu Z; Lei M; Cheng J; Guo X; Zhang L; Lin S; Yuan Q
Int Immunopharmacol; 2022 Aug; 109():108732. PubMed ID: 35468364
[TBL] [Abstract][Full Text] [Related]
13. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
16. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract][Full Text] [Related]
17. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.
Peng J; Zou D; Han L; Yin Z; Hu X
Front Immunol; 2021; 12():778276. PubMed ID: 35095850
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Huang S; Wu J; Li S; Li X; Zeng R; Tang Y; Tang J; Ben X; Zhang D; Xie L; Zhou H; Chen G; Wang S; Gao Z; Wu H; Chen R; Xu F; Qiao G
Lung Cancer; 2023 Dec; 186():107401. PubMed ID: 37844351
[TBL] [Abstract][Full Text] [Related]
19. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
